BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

...hired David Hollander as chief R&D officer, effective Nov. 11. He was CMO, SVP at Ora Inc....
BioCentury | Sep 15, 2017
Company News

Harbour gets Chinese rights to HanAll's biologics

...In November, HanAll hopes to begin a Phase II trial of the candidate with partner Ora Inc....
...Seoul, South Korea Harbour BioMed , Shanghai, China Business: Autoimmune, Ophthalmic Chris Lieu HL036 HL161 HanAll Biopharma Co. Ltd. Harbour BioMed Ora Inc. Neonatal...
BioCentury | Sep 12, 2017
Company News

Harbour gets Chinese rights to HanAll's biologics

...In November, HanAll hopes to begin a Phase II trial of the candidate with partner Ora Inc....
...at Sanofi (Euronext:SAN; NYSE:SNY). HanAll gained KrW700 to KrW13,000 on Tuesday. Chris Lieu HL036 HL161 HanAll Biopharma Co. Ltd. Harbour BioMed Ora Inc. Neonatal...
BioCentury | Jun 8, 2015
Company News

Portola, Ora deal

...The companies declined to disclose financial terms. Portola Pharmaceuticals Inc. (NASDAQ:PTLA), South San Francisco, Calif. Ora Inc....
BioCentury | Jan 14, 2013
Company News

Eye Therapies, Bausch + Lomb deal

...treat ocular redness. The product, which uses low-dose brimonidine, was developed with private research organization Ora Inc....
Items per page:
1 - 5 of 5
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

...hired David Hollander as chief R&D officer, effective Nov. 11. He was CMO, SVP at Ora Inc....
BioCentury | Sep 15, 2017
Company News

Harbour gets Chinese rights to HanAll's biologics

...In November, HanAll hopes to begin a Phase II trial of the candidate with partner Ora Inc....
...Seoul, South Korea Harbour BioMed , Shanghai, China Business: Autoimmune, Ophthalmic Chris Lieu HL036 HL161 HanAll Biopharma Co. Ltd. Harbour BioMed Ora Inc. Neonatal...
BioCentury | Sep 12, 2017
Company News

Harbour gets Chinese rights to HanAll's biologics

...In November, HanAll hopes to begin a Phase II trial of the candidate with partner Ora Inc....
...at Sanofi (Euronext:SAN; NYSE:SNY). HanAll gained KrW700 to KrW13,000 on Tuesday. Chris Lieu HL036 HL161 HanAll Biopharma Co. Ltd. Harbour BioMed Ora Inc. Neonatal...
BioCentury | Jun 8, 2015
Company News

Portola, Ora deal

...The companies declined to disclose financial terms. Portola Pharmaceuticals Inc. (NASDAQ:PTLA), South San Francisco, Calif. Ora Inc....
BioCentury | Jan 14, 2013
Company News

Eye Therapies, Bausch + Lomb deal

...treat ocular redness. The product, which uses low-dose brimonidine, was developed with private research organization Ora Inc....
Items per page:
1 - 5 of 5